Navigation Links
Auxogyn licenses noninvasive embryo assessment technology from Stanford University
Date:10/3/2010

MENLO PARK, Calif. October 4, 2010 Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.

The technology licensed from Stanford is described in a publication titled 'Non-invasive imaging of human embryos before embryonic genome activation predicts development to the blastocyst stage,' now appearing in the online edition of Nature Biotechnology. This landmark study demonstrated, for the first time, that human embryo fate is already determined at the four-cell stage of development. The article is authored by Professor Renee Reijo Pera, Dr. Connie Wong, Dr. Kevin Loewke, Dr. Nancy Bossert, Dr. Barry Behr, Dr. Christopher De Jonge and Dr. Thomas Baer and showed that measuring a unique set of non‑invasive imaging parameters by day 2 may allow an embryologist to predict the embryos that will reach the blastocyst (day 5) stage of development with a very high degree of accuracy.

"Blastocyst formation is a critical time point in human embryo development and provides more objective criteria for selecting which embryo(s) to transfer," said Lissa Goldenstein, president and chief executive officer of Auxogyn, Inc. "For years, researchers have searched for ways to predict the embryos most likely to reach the blastocyst stage in order to enable earlier transfer and ultimately improve live birth rates for in vitro fertilization procedures."

"Building on the technology licensed from Stanford, we are developing a product that assesses early embryo viability at the 4-cell stage. We believe that generating key clinical data assessments may enable embryologists to improve the effectiveness of in vitro fertilization (IVF) procedures while providing women experiencing infertility the highest quality of patient care," continued Ms. Goldenstein.


'/>"/>

Contact: Angela Bitting
a.bitting@comcast.net
925-202-6211
AB Corporate Communications
Source:Eurekalert

Related biology news :

1. Brown licenses potential muscular dystrophy treatment to Tivorsan Pharmaceuticals
2. U of M licenses unique plant protection product
3. UC Riverside licenses technology to OlFactor Laboratories, Inc.
4. UT-Battelle licenses tissue regeneration technologies to NellOne Therapeutics, Inc.
5. Virginia Tech licenses GenoCAD source code to ISCB
6. TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... a new line of intelligent tools designed, tuned and optimized exclusively for Okuma ... 12–17 in Chicago. The result of a collaboration among several companies with expertise ...
(Date:6/22/2016)... DIEGO , June 22, 2016 ... that will allow them to produce up to ... from one lot within one week. These high-quality, ... time laboriously preparing cells and spend more time ... possible through a proprietary, high-volume manufacturing process that ...
Breaking Biology Technology: